These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38157111)

  • 1. PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative "triplet" for oligometastatic hormone sensitive prostate cancer patients.
    Francolini G; Porreca A; Facchini G; Santini D; Bruni A; Simoni N; Trovò M; Osti MF; Fornarini G; Sisani M; Di Cataldo V; Detti B; Garlatti P; Bertini N; Serni S; Minervini A; Livi L
    Med Oncol; 2023 Dec; 41(1):39. PubMed ID: 38157111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stereotactic body radiotherapy (SBRT) versus androgen deprivation therapy (ADT) for oligometastatic prostate cancer: protocol for a prospective randomised control clinical trial.
    Zhao X; Wang T; Ye Y; Li J; Gao X; Zhang H
    BMJ Open; 2022 Sep; 12(9):e051371. PubMed ID: 36180115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for Evaluating the Efficacy and Safety of Radiotherapy for Prostate and Oligometastatic Lesions in Patients With Low-Burden Sensitive Oligometastatic Prostate Cancer: An Open, Exploratory Pilot Clinical Trial.
    Xu B; Zhao X; Feng Z; Li J; Liang Y; Zhang W; Chen L; Shen X; Qu M; Gao X; Zhang H
    Cancer Control; 2024; 31():10732748241274595. PubMed ID: 39180187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES.
    Armstrong AJ; Iguchi T; Azad AA; Villers A; Alekseev B; Petrylak DP; Szmulewitz RZ; Alcaraz A; Shore ND; Holzbeierlein J; Gomez-Veiga F; Rosbrook B; Zohren F; Haas GP; Gourgiotti G; El-Chaar N; Stenzl A
    Eur Urol; 2023 Aug; 84(2):229-241. PubMed ID: 37179240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
    Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Prospective Trials Assessing the Role of Stereotactic Body Radiation Therapy for Metastasis-directed Treatment in Oligometastatic Genitourinary Cancers.
    Huynh MA; Tang C; Siva S; Berlin A; Hannan R; Warner A; Koontz B; De Meeleer G; Palma D; Ost P; Tran PT
    Eur Urol Oncol; 2023 Feb; 6(1):28-38. PubMed ID: 36283936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Detected via Prostate-specific Membrane Antigen Positron Emission Tomography.
    Kneebone A; Hruby G; Ainsworth H; Byrne K; Brown C; Guo L; Guminski A; Eade T
    Eur Urol Oncol; 2018 Dec; 1(6):531-537. PubMed ID: 31158100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LUNAR: a randomized Phase 2 study of
    Ma TM; Czernin J; Felix C; Alano R; Wilhalme H; Valle L; Steinberg ML; Dahlbom M; Reiter RE; Rettig MB; Cao M; Calais J; Kishan AU
    BJU Int; 2023 Jul; 132(1):65-74. PubMed ID: 36797449
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in Management of Oligometastatic Hormone-Sensitive Prostate Cancer.
    Kothari G; Ost P; Cheung P; Blanchard P; Tree AC; van As NJ; Lo SS; Moghanaki D; Loblaw A; Siva S
    Curr Oncol Rep; 2019 Mar; 21(5):43. PubMed ID: 30919165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer.
    Saxby H; Boussios S; Mikropoulos C
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by [18F]fluoromethylcholine PET/CT.
    Bouman-Wammes EW; van Dodewaard-De Jong JM; Dahele M; Cysouw MCF; Hoekstra OS; van Moorselaar RJA; Piet MAH; Verberne HJ; Bins AD; Verheul HMW; Slotman BJ; Oprea-Lager DE; Van den Eertwegh AJM
    Clin Genitourin Cancer; 2017 Oct; 15(5):e773-e782. PubMed ID: 28462855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic body radiotherapy for bone oligometastatic disease in prostate cancer.
    Patel PH; Chaw CL; Tree AC; Sharabiani M; van As NJ
    World J Urol; 2019 Dec; 37(12):2615-2621. PubMed ID: 31346760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A narrative review of oligometastatic prostate cancer-an evolving paradigm.
    Sritharan K; Rieu R; Tree A
    Ann Palliat Med; 2021 May; 10(5):5969-5987. PubMed ID: 33752437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial stereotactic body radiation therapy for oligometastatic prostate cancer detected by novel PET-based radiotracers.
    Kwon DH; Shakhnazaryan N; Shui D; Hong JC; Mohamad O; de Kouchkovsky I; Borno HT; Bose R; Chou J; Desai A; Fong L; Friedlander TW; Koshkin VS; Aggarwal RR; Feng FY; Hope TA; Small EJ
    Urol Oncol; 2023 Mar; 41(3):145.e7-145.e15. PubMed ID: 36435709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Metachronous oligometastatic prostate cancer-the more the better or only local treatment?].
    Steuber T; Maurer T; Miller K
    Urologe A; 2021 Dec; 60(12):1534-1545. PubMed ID: 34734294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fractionated stereotactic body radiotherapy for up to five prostate cancer oligometastases: Interim outcomes of a prospective clinical trial.
    Bowden P; See AW; Frydenberg M; Haxhimolla H; Costello AJ; Moon D; Ruljancich P; Grummet J; Crosthwaite A; Pranavan G; Peters JS; So K; Gwini SM; McKenzie DP; Nolan S; Smyth LML; Everitt C
    Int J Cancer; 2020 Jan; 146(1):161-168. PubMed ID: 31199504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of radiotherapy in oligometastatic hormone-sensitive prostate cancer.
    Abdel-Aty H; James ND
    Curr Opin Urol; 2022 May; 32(3):277-282. PubMed ID: 35249966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Radiotherapy for Lesions Detected via
    Pan J; Wei Y; Zhang T; Liu C; Hu X; Zhao J; Gan H; Liu W; Zhu B; Wu J; Wang B; Song S; Ye D; Zhu Y
    Eur Urol Oncol; 2022 Aug; 5(4):420-427. PubMed ID: 35304107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.